Whalesbook
Bajaj Healthcare Limited announced a significant uptick in its third-quarter financial performance, with net profit surging by 34.2% year-on-year to ₹15.7 crore. This robust growth outpaced the ₹11.7 crore profit recorded in the same period last fiscal.
Strong Revenue and Profitability
The company's top line saw a healthy expansion, with revenue climbing 31.3% to ₹161.2 crore from ₹122.8 crore in the prior year's third quarter. Profitability metrics also improved markedly. Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) grew at a faster clip of 42.4% year-on-year, reaching ₹30.8 crore compared to ₹21.6 crore a year ago.
This accelerated EBITDA growth points to enhanced operational efficiencies and effective cost management. The company highlighted improved operating leverage as a key factor.
Margin Expansion and Sector Context
Bajaj Healthcare successfully expanded its operating margin to 19.1% in the quarter, up from 17.6% in the corresponding quarter of the previous year. This improvement is particularly noteworthy given the prevailing sector-wide cost pressures. The enhanced margin performance underscores the company's commitment to operational excellence and disciplined execution strategies.
The strong Q3 results come shortly after Bajaj Healthcare secured exclusive rights to manufacture and market Magnesium L Threonate in India, a development that may contribute to future growth avenues.
Bajaj Healthcare shares concluded trading at ₹389.30 on the National Stock Exchange (NSE) on January 16, 2026, experiencing a slight decline of 1.23%.